RSV vaccine manufacturers vie for market share in second year of vaccinations
Pfizer, GSK and Moderna’s competition to supply new respiratory syncytial virus (RSV) vaccines is on Wall Street’s watch list as the companies will report their earnings later this week.
POPULAR POSTS
Poland prepares for peaking floods
September 20, 2024
Italy evacuates thousands as Boris hits the north
September 20, 2024
China and the US race to tame nuclear fusion for clean energy
September 20, 2024
LIVE STREAM